Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Daly ME, Simone CB, Redman MW, Hsieh MH, Hesketh PJ, Hu C, Monjazeb AM, Steuer CE, Ganti AK, Kashani R, Bauman JR, Feliciano JL, Moon J, Ku K, Le-Lindqwister N, Baschnagel AM, Maraboyina S, Sherwood GB, Almquist D, Higgins KA, Gray JE, Bradley JD, Kelly K. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet. 2026 Oct 03; 408(10562):1313-1325.
-
Yang L, Raza F, Song J, Xi X, Yang S, Xiao H, Jiang L, Chen W, Zhong J, Qiu M, Su J. Copper arsenite-loaded hydrogel for breast cancer therapy via cuproptosis-induced immunity synergized with arsenic chemotherapy. Colloids Surf B Biointerfaces. 2026 Dec; 268(Pt 1):116023.
-
Chow R, Zhang D, Chai GW, Yuen M, Lu A, Fortuna V, Talwar S, Boldt G, Lock M, Lee SF, Eng L, Iihara H, Affronti ML, Saito M, Aapro M, Hesketh PJ, Scotté F, Ruhlmann CH, Leigh J. Olanzapine (10 mg vs 5 mg vs 2.5 mg) for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) - a systematic review and network meta-analysis. Support Care Cancer. 2026 Jul 16; 34(8).
-
Weiss GJ, Loftus JC, Mallery DW, Tran NL. Structure-guided identification and biological evaluation of reversible EGFR C797S inhibitors. Sci Rep. 2026 May 04; 16(1).
-
Kaddoura M, Wiedmeier-Nutor JE, Gupta VA, Jelinek T, Ziccheddu B, Shivaram S, Tang H, Owens RW, Sevcikova T, Fonseca R, Durante M, Diamond B, Zhao L, Zhu YX, Shi CX, Matulis SM, Mitsiades CS, Landgren O, Usmani S, Hajek R, Chesi M, Bergsagel PL, Braggio E, Boise LH, Fonseca R, Kumar S, Maura F, Baughn LB. Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH). Blood. 2026 Apr 02; 147(14):1598-1610.
-
Porto SA, Birdsall GA, Harper NW, Honeywell ME, Leighow SM, Naylor TE, Ward KM, Wesley MK, Pritchard JR, Lee MJ. Genome-wide profiling identifies the genetic dependencies of cell death following EGFR inhibition. J Biol Chem. 2026 May; 302(5):111414.
-
Abbas G, Bokhari TH, Iqbal MA, Rehman S, Ali A. Mechanosynthesis and computational studies of new imidazole-based selenium adducts as potential anticancer agents against human prostate and cervical cancer. Future Med Chem. 2026 05; 18(9):1059-1069.
-
Hansen DK, Lu X, Castaneda Puglianini O, Zhang E, Usmani SZ, Sachdev R, Perciavalle M, De Wiest D, Huo S, Lee S, Qureshi ZP, Jagannath S. Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2026 Mar; 26(3):369-378.
-
Yu JX, Suh JM, Popova KD, Garcia K, Joshi T, Culbertson B, Spinelli JB, Subramanyam V, Lou K, Charbonneau T, Shokat KM, Weissman J, Goodarzi H. The GENEVA platform models tumor mosaicism to reveal variations of responses to KRAS inhibitors and identify improved drug combinations. Nat Cancer. 2026 Mar; 7(3):522-537.
-
Meade K, Blake J, Giuliano KK. A Scoping Review: The Impact of IV Smart Pump Air-in-Line Alarms in Oncology Care. Clin J Oncol Nurs. 2025 Nov 19; 29(6):E167-E177.